Diacerein alleviates kidney injury through attenuating inflammation and oxidative stress in obese insulin-resistant rats

Free Radical Biology and Medicine

Volumn 115, Issue , 2018, Pages 146-155

  Chueakula, Nuttawud ^a   Jaikumkao, Krit ^a   Arjinajarn, Phatchawan ^b   Pongchaidecha, Anchalee ^a   Chatsudthipong, Varanuj ^c   Chattipakorn, Nipon ^a   Lungkaphin, Anusorn ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c NONE   (Thailand)

Author keywords

Diacerein; Inflammation; Insulin resistance; Kidney function; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CREATININE; DIACEREIN; HEME OXYGENASE 1; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; METFORMIN; ORGANIC ANION TRANSPORTER 3; PROTEIN KINASE C ALPHA; TRANSCRIPTION FACTOR NRF2; ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ORGANIC ANION TRANSPORTER; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; LIPID DIET; MALE; MICROALBUMINURIA; NEPHRITIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RENAL PROTECTION; TREATMENT DURATION; ANIMAL; BLOOD; DISEASE MODEL; HUMAN; KIDNEY; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CREATININE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY; OBESITY; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 85035784485     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.11.021     Document Type: Article

References (67)

1. Kovesdy, C.P., Furth, S.L., Zoccali, C., C. World Kidney Day Steering. Obesity and kidney disease: hidden consequences of the epidemic. Blood Purif. 43 (2017), 346–354.
2. Wellen, K.E., Hotamisligil, G.S., Obesity-induced inflammatory changes in adipose tissue. J. Clin. Investig. 112 (2003), 1785–1788.
3. Wellen, K.E., Hotamisligil, G.S., Inflammation, stress, and diabetes. J. Clin. Investig. 115 (2005), 1111–1119.
4. Bastard, J.P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., Capeau, J., Feve, B., Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17 (2006), 4–12.
5. Chen, J., Muntner, P., Hamm, L.L., Jones, D.W., Batuman, V., Fonseca, V., Whelton, P.K., He, J., The metabolic syndrome and chronic kidney disease in U.S. adults. Ann. Intern Med. 140 (2004), 167–174.
6. Deji, N., Kume, S., Araki, S., Soumura, M., Sugimoto, T., Isshiki, K., Chin-Kanasaki, M., Sakaguchi, M., Koya, D., Haneda, M., Kashiwagi, A., Uzu, T., Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am. J. Physiol. Ren. Physiol. 296 (2009), 118–126.
7. Zeisberg, M., Bonner, G., Maeshima, Y., Colorado, P., Muller, G.A., Strutz, F., Kalluri, R., Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am. J. Pathol. 159 (2001), 1313–1321.
8. Boutaud, A., Borza, D.B., Bondar, O., Gunwar, S., Netzer, K.O., Singh, N., Ninomiya, Y., Sado, Y., Noelken, M.E., Hudson, B.G., Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J. Biol. Chem. 275 (2000), 30716–30724.
9. Wahba, I.M., Mak, R.H., Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2 (2007), 550–562.
10. Knight, S.F., Imig, J.D., Obesity, insulin resistance, and renal function. Microcirculation 14 (2007), 349–362.
11. Keaney, J.F. Jr., Larson, M.G., Vasan, R.S., Wilson, P.W., Lipinska, I., Corey, D., Massaro, J.M., Sutherland, P., Vita, J.A., Benjamin, E.J., Framingham, S., Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 23 (2003), 434–439.
12. Moreno-Manzano, V., Ishikawa, Y., Lucio-Cazana, J., Kitamura, M., Selective involvement of superoxide anion, but not downstream compounds hydrogen peroxide and peroxynitrite, in tumor necrosis factor-alpha-induced apoptosis of rat mesangial cells. J. Biol. Chem. 275 (2000), 12684–12691.
13. Zhou, X., Yang, G., Davis, C.A., Doi, S.Q., Hirszel, P., Wingo, C.S., Agarwal, A., Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells. Kidney Int. 65 (2004), 139–147.
14. Nair, A.R., Elks, C.M., Vila, J., Del Piero, F., Paulsen, D.B., Francis, J., A blueberry-enriched diet improves renal function and reduces oxidative stress in metabolic syndrome animals: potential mechanism of TLR4-MAPK signaling pathway. PLoS One, 9, 2014, e111976.
15. Zou, Y., Hong, B., Fan, L., Zhou, L., Liu, Y., Wu, Q., Zhang, X., Dong, M., Protective effect of puerarin against beta-amyloid-induced oxidative stress in neuronal cultures from rat hippocampus: involvement of the GSK-3beta/Nrf2 signaling pathway. Free Radic. Res. 47 (2013), 55–63.
16. Zheng, H., Whitman, S.A., Wu, W., Wondrak, G.T., Wong, P.K., Fang, D., Zhang, D.D., Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60 (2011), 3055–3066.
17. Motohashi, H., Sakurai, Y., Saito, H., Masuda, S., Urakami, Y., Goto, M., Fukatsu, A., Ogawa, O., Inui, K., Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13 (2002), 866–874.
18. Habu, Y., Yano, I., Okuda, M., Fukatsu, A., Inui, K., Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney. Biochem. Pharmacol. 69 (2005), 993–999.
19. Burckhardt, G., Burckhardt, B.C., In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb. Exp. Pharmacol. 201 (2011), 29–104.
20. Phatchawan, A., Chutima, S., Varanuj, C., Anusorn, L., Decreased renal organic anion transporter 3 expression in type 1 diabetic rats. Am. J. Med. Sci. 347 (2014), 221–227.
21. Sharma, K., Karl, B., Mathew, A.V., Gangoiti, J.A., Wassel, C.L., Saito, R., Pu, M., Sharma, S., You, Y.H., Wang, L., Diamond-Stanic, M., Lindenmeyer, M.T., Forsblom, C., Wu, W., Ix, J.H., Ideker, T., Kopp, J.B., Nigam, S.K., Cohen, C.D., Groop, P.H., Barshop, B.A., Natarajan, L., Nyhan, W.L., Naviaux, R.K., Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J. Am. Soc. Nephrol. 24 (2013), 1901–1912.
22. Fidelix, T.S., Macedo, C.R., Maxwell, L.J., Fernandes Moca Trevisani, V., Diacerein for osteoarthritis. Cochrane Database Syst. Rev., 2, 2014, CD005117.
23. Nicolas, P., Tod, M., Padoin, C., Petitjean, O., Clinical pharmacokinetics of diacerein. Clin. Pharmacokinet. 35 (1998), 347–359.
24. Torina, A.G., Reichert, K., Lima, F., de Souza Vilarinho, K.A., de Oliveira, P.P., do Carmo, H.R., de Carvalho, D.D., Saad, M.J., Sposito, A.C., Petrucci, O., Diacerein improves left ventricular remodeling and cardiac function by reducing the inflammatory response after myocardial infarction. PLoS One, 10, 2015, e0121842.
25. Mendes, A.F., Caramona, M.M., de Carvalho, A.P., Lopes, M.C., Diacerhein and rhein prevent interleukin-1beta-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha. Pharmacol. Toxicol. 91 (2002), 22–28.
26. Zhou, Y.X., Xia, W., Yue, W., Peng, C., Rahman, K., Zhang, H., Rhein, A review of Pharmacological activities. Evid. Based Complement Altern. Med., 2015, 578107.
27. Refaie, M.M., Amin, E.F., El-Tahawy, N.F., Abdelrahman, A.M., Possible protective effect of diacerein on doxorubicin-induced nephrotoxicity in rats. J. Toxicol., 2016, 9507563.
28. Jatwa, R., Kar, A., Anti-inflammatory and anti-peroxidative roles of diacerein are possibly mediated through an alteration in thyroid functions in animal model of inflammation. Fundam. Clin. Pharmacol. 23 (2009), 465–471.
29. Apaijai, N., Chinda, K., Palee, S., Chattipakorn, S., Chattipakorn, N., Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. PLoS One, 9, 2014, e102374.
30. Tunapong, W., Apaijai, N., Yasom, S., Tanajak, P., Wanchai, K., Chunchai, T., Kerdphoo, S., Eaimworawuthikul, S., Thiennimitr, P., Pongchaidecha, A., Lungkaphin, A., Pratchayasakul, W., Chattipakorn, S.C., Chattipakorn, N., Chronic treatment with prebiotics, probiotics and synbiotics attenuated cardiac dysfunction by improving cardiac mitochondrial dysfunction in male obese insulin-resistant rats. Eur. J. Nutr., 2017, 1–14.
31. Feng, M., Whitesall, S., Zhang, Y., Beibel, M., D'Alecy, L., DiPetrillo, K., Validation of volume-pressure recording tail-cuff blood pressure measurements. Am. J. Hypertens. 21 (2008), 1288–1291.
32. Senn, S., Analysis of serial measurements in medical research. BMJ, 300, 1990, 680.
33. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 1985 (412-409).
34. Yu, C., Qi, D., Sun, J.F., Li, P., Fan, H.Y., Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-kappaB activities. Sci. Rep., 5, 2015, 11822.
35. Mount, P., Davies, M., Choy, S.W., Cook, N., Power, D., Obesity-related chronic kidney disease-the role of lipid metabolism. Metabolites 5 (2015), 720–732.
36. Fazeli, G., Stopper, H., Schinzel, R., Ni, C.W., Jo, H., Schupp, N., Angiotensin II induces DNA damage via AT1 receptor and NADPH oxidase isoform Nox4. Mutagenesis 27 (2012), 673–681.
37. Banday, A.A., Lokhandwala, M.F., Oxidative stress-induced renal angiotensin AT1 receptor upregulation causes increased stimulation of sodium transporters and hypertension. Am. J. Physiol. Ren. Physiol. 295 (2008), 698–706.
38. Decleves, A.E., Sharma, K., Obesity and kidney disease: differential effects of obesity on adipose tissue and kidney inflammation and fibrosis. Curr. Opin. Nephrol. Hypertens. 24 (2015), 28–36.
39. Palaniappan, L., Carnethon, M., Fortmann, S.P., Association between microalbuminuria and the metabolic syndrome: nhanes III. Am. J. Hypertens. 16 (2003), 952–958.
40. Kurella, M., Lo, J.C., Chertow, G.M., Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol. 16 (2005), 2134–2140.
41. Takeda, M., Sekine, T., Endou, H., Regulation by protein kinase C of organic anion transport driven by rat organic anion transporter 3 (rOAT3). Life Sci. 67 (2000), 1087–1093.
42. Jaikumkao, K., Pongchaidecha, A., Chattipakorn, N., Chatsudthipong, V., Promsan, S., Arjinajarn, P., Lungkaphin, A., Atorvastatin improves renal organic anion transporter 3 and renal function in gentamicin-induced nephrotoxicity in rats. Exp. Physiol. 101 (2016), 743–753.
43. Promsan, S., Jaikumkao, K., Pongchaidecha, A., Chattipakorn, N., Chatsudthipong, V., Arjinajarn, P., Pompimon, W., Lungkaphin, A., Pinocembrin attenuates gentamicin-induced nephrotoxicity in rats. Can. J. Physiol. Pharmacol., 2016, 1–11.
44. Gustafson, B., Adipose tissue, inflammation and atherosclerosis. J. Atheroscler. Thromb. 17 (2010), 332–341.
45. Ruan, X., Guan, Y., Metabolic syndrome and chronic kidney disease. J. Diabetes 1 (2009), 236–245.
46. Kamei, N., Tobe, K., Suzuki, R., Ohsugi, M., Watanabe, T., Kubota, N., Ohtsuka-Kowatari, N., Kumagai, K., Sakamoto, K., Kobayashi, M., Yamauchi, T., Ueki, K., Oishi, Y., Nishimura, S., Manabe, I., Hashimoto, H., Ohnishi, Y., Ogata, H., Tokuyama, K., Tsunoda, M., Ide, T., Murakami, K., Nagai, R., Kadowaki, T., Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 281 (2006), 26602–26614.
47. Xu, M.X., Wang, M., Yang, W.W., Gold-quercetin nanoparticles prevent metabolic endotoxemia-induced kidney injury by regulating TLR4/NF-kappaB signaling and Nrf2 pathway in high fat diet fed mice. Int. J. Nanomed. 12 (2017), 327–345.
48. Fernandez-Sanchez, A., Madrigal-Santillan, E., Bautista, M., Esquivel-Soto, J., Morales-Gonzalez, A., Esquivel-Chirino, C., Durante-Montiel, I., Sanchez-Rivera, G., Valadez-Vega, C., Morales-Gonzalez, J.A., Inflammation, oxidative stress, and obesity. Int. J. Mol. Sci. 12 (2011), 3117–3132.
49. Chang, J.W., Kim, C.S., Kim, S.B., Park, S.K., Park, J.S., Lee, S.K., C-reactive protein induces NF-kappaB activation through intracellular calcium and ROS in human mesangial cells. Nephron Exp. Nephrol. 101 (2005), 65–172.
50. Vaziri, N.D., Bai, Y., Ni, Z., Quiroz, Y., Pandian, R., Rodriguez-Iturbe, B., Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J. Pharmacol. Exp. Ther. 323 (2007), 85–93.
51. Kobayashi, M., Yamamoto, M., Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid. Redox Signal. 7 (2005), 385–394.
52. Dougados, M., Nguyen, M., Berdah, L., Mazieres, B., Vignon, E., Lequesne, M., Group, E.I.S., Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: echodiah, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 44 (2001), 2539–2547.
53. Quintao, N.L., Medeiros, R., Santos, A.R., Campos, M.M., Calixto, J.B., The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice. Anesth. Analg. 101 (2005), 1763–1769.
54. Cardoso, C.R.L., Leite, N.C., Carlos, F.O., Loureiro, A.A., Viegas, B.B., Salles, G.F., Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Care 40 (2017), 1356–1363.
55. Piovesan, F., Tres, G.S., Moreira, L.B., Andrades, M.E., Lisboa, H.K., Fuchs, S.C., Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: a randomized controlled trial. PLoS One, 12, 2017, e0186554.
56. Malaguti, C., Vilella, C.A., Vieira, K.P., Souza, G.H., Hyslop, S., Zollner Rde, L., Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice. Int. Immunopharmacol. 8 (2008), 782–791.
57. Villar, M.M., Martinez-Abundis, E., Preciado-Marquez, R.O., Gonzalez-Ortiz, M., Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch. Endocrinol. Metab. 61 (2017), 188–192.
58. Tobar, N., Oliveira, A.G., Guadagnini, D., Bagarolli, R.A., Rocha, G.Z., Araujo, T.G., Santos-Silva, J.C., Zollner, R.L., Boechat, L.H., Carvalheira, J.B., Prada, P.O., Saad, M.J., Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology 152 (2011), 4080–4093.
59. Li, C., Culver, S.A., Quadri, S., Ledford, K.L., Al-Share, Q.Y., Ghadieh, H.E., Najjar, S.M., Siragy, H.M., High-fat diet amplifies renal renin angiotensin system expression, blood pressure elevation, and renal dysfunction caused by Ceacam1 null deletion. Am. J. Physiol. Endocrinol. Metab. 309 (2015), 802–810.
60. Toke, A., Meyer, T.W., Hemodynamic effects of angiotensin II in the kidney. Contrib. Nephrol. 135 (2001), 34–46.
61. Arima, S., Kohagura, K., Xu, H.L., Sugawara, A., Abe, T., Satoh, F., Takeuchi, K., Ito, S., Nongenomic vascular action of aldosterone in the glomerular microcirculation. J. Am. Soc. Nephrol. 14 (2003), 2255–2263.
62. DeMarco, V.G., Aroor, A.R., Sowers, J.R., The pathophysiology of hypertension in patients with obesity. Nat. Rev. Endocrinol. 10 (2014), 364–376.
63. Sun, Z., Aging, arterial stiffness, and hypertension. Hypertension 65 (2015), 252–256.
64. Bharti, R., Dey, G., Ojha, P.K., Rajput, S., Jaganathan, S.K., Sen, R., Mandal, M., Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene 35 (2016), 3965–3975.
65. Tamura, T., Yokoyama, T., Ohmori, K., Effects of diacerein on indomethacin-induced gastric ulceration. Pharmacology 63 (2001), 228–233.
66. Zhao, Y.L., Zhou, G.D., Yang, H.B., Wang, J.B., Shan, L.M., Li, R.S., Xiao, X.H., Rhein protects against acetaminophen-induced hepatic and renal toxicity. Food Chem. Toxicol. 49 (2011), 1705–1710.
67. Wang, Y., Ding, M., Chaudhari, S., Ding, Y., Yuan, J., Stankowska, D., He, S., Krishnamoorthy, R., Cunningham, J.T., Ma, R., Nuclear factor kappaB mediates suppression of canonical transient receptor potential 6 expression by reactive oxygen species and protein kinase C in kidney cells. J. Biol. Chem. 288 (2013), 12852–12865.